COMMUNIQUÉS West-GlobeNewswire

Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy
28/09/2019
Supports Recent Addition of HER2 Blockade Therapy to NCCN Guidelines for Treatment Refractory mCRC Patients BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) -- Guardant Health and the National Cancer Center Hospital [...]
Immunomedics Provides Corporate Update
28/09/2019
Sacituzumab Govitecan Achieves a 29 Percent Objective Response Rate in 35 Patients With Advanced Urothelial Cancer Who Failed Prior Platinum-Based Regimens and Immunotherapy Future Steps Include Discussing [...]
XBiotech annonce la présentation orale de l'essai clinique évaluant le bermekimab dans le traitement de la dermatite atopique lors du prochain congrès EADV 2019 à Madrid, en Espagne
28/09/2019
Les résultats de la phase 2 de l'essai clinique par la société seront présentés par le Dr Alice Gottlieb le samedi 12 octobre 2019 AUSTIN, Texas, 28 sept. 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ : XBIT) a annoncé la [...]
G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival
28/09/2019
-- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung cancer (SCLC) patients receiving [...]
Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma
28/09/2019
Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64 [...]
Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
28/09/2019
New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/09/2019
CRESTWOOD, Ky., and WALTHAM Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
27/09/2019
DUBLIN, Ireland and CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat [...]
Iovance Biotherapeutics to Present at Upcoming Conferences
27/09/2019
SAN CARLOS, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL [...]
Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH
27/09/2019
NDA supported by positive interim analysis results from REGENERATE Phase 3 study demonstrating OCA’s improvement of liver fibrosis without worsening of NASH NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Intercept [...]
Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference
27/09/2019
EMERYVILLE, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, [...]
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
27/09/2019
CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable [...]
Shineco, Inc. Reports Fiscal Year 2019 Financial Results
27/09/2019
BEIJING, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and other [...]
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
27/09/2019
RADNOR, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat [...]
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27/09/2019
FREMONT, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 100 [...]
Supertooth Dental Group Acquires the Latest Technology to Allow them to Offer Same-Day Dental Crowns
27/09/2019
BETHESDA, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Supertooth Dental Group has just added the Glidwell dental restoration milling machine to their already high-tech offices. With this new piece of equipment, the dentists [...]
Misonix, Inc. Completes Acquisition of Regenerative Medical Company Solsys Medical
27/09/2019
FARMINGDALE, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, [...]
Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference
27/09/2019
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet [...]
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association
27/09/2019
Nabriva publication of Phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with community-acquired bacterial pneumonia (CABP) DUBLIN [...]

Pages